Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
11 Results for "
α-Synuclein inclusions
" in MedChemExpress (MCE) Product Catalog:
Products (11)
11 Results for "α-Synuclein inclusions" in MCE Product Catalog:
Target:
Art. -Nr.: HY-152552
CAS. Nr.: 2883627-64-1
Target:
Forschungsgebiete:
α-Synuclein inhibitor 8 is an active inhibitor of α-Synuclein with an IC50 value of 2.5 µM. α-Synuclein inhibitor 8 has highly inhibition on the aggregation and disaggregation of α-Synuclein fibers. α-Synuclein inhibitor 8 reduces the formation of inclusions in neurons that can repairs damage neurons and improves Parkinson’s disease (PD)-like symptoms. α-Synuclein inhibitor 8 has high antioxidant activity and low cytotoxicity .
Art. -Nr.: HY-156435
Target:
Forschungsgebiete:
tau protein/α-synuclein-IN-1 is a dual inhibitor of tau protein and α-synuclein. tau protein/α-synuclein-IN-1 reduces α-syn inclusions development in M17D neuroblastoma cells. tau protein/α-synuclein-IN-1 can be used in study Alzheimer’s disease .
Art. -Nr.: HY-159945
Target:
Forschungsgebiete:
Tau Protein/α-synuclein-IN-2 (Compound 14T) is a blood-brain barrier penetrating tau and α-syn inhibitor. Through its thiourea linker structure, Tau Protein/α-synuclein-IN-2 dose-dependently reduces α-syn oligomerization. In biosensor cells, Tau Protein/α-synuclein-IN-2 prevents the seeding effect of tau aggregation. In the M17D neuroblastoma model, Tau Protein/α-synuclein-IN-2 exhibits anti-inclusion effects. Additionally, Tau Protein/α-synuclein-IN-2 reduces Aβ plaque formation. Tau Protein/α-synuclein-IN-2 holds promise for Alzheimer's disease and Parkinson's disease research.
Art. -Nr.: HY-184815
CAS. Nr.: 2883627-67-4
Forschungsgebiete:
α-Synuclein-IN-20 is an inhibitor of α-synuclein (α-Synuclein) with an IC50 of 4.1 μM against human α-Syn. α-Synuclein-IN-20 exerts anti-aggregation effects by stabilizing the native conformation of α-Syn, inhibiting the formation of β-sheet aggregates and inclusion bodies, and dissociating mature fibrils into functional monomers. α-Synuclein-IN-20 scavenges ROS, protects and repairs dopaminergic neurons, ameliorates Parkinson's disease-like symptoms, and shows low cytotoxicity. α-Synuclein-IN-20 can be used for research related to Parkinson's disease .
Art. -Nr.: HY-119857
CAS. Nr.: 304896-21-7
Synonyms: SIRT2 Inhibitor,Inactive Control
Target:
Forschungsgebiete:
AGK7 is a potent inhibitor of sirtuin 2 (SIRT2). AGK7 rescues alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. AGK7 protects against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease .
Art. -Nr.: HY-184818
CAS. Nr.: 2883627-62-9
Forschungsgebiete:
α-Synuclein-IN-23 is an inhibitor of α-synuclein with an IC50 of 2.1 μM. α-Synuclein-IN-23 dissociates preformed α-synuclein aggregates, scavenges reactive oxygen species (ROS), and inhibits the formation of α-synuclein inclusions in neuronal cells. α-Synuclein-IN-23 can be used for the research of Parkinson's disease .
Art. -Nr.: HY-184816
CAS. Nr.: 2883627-65-2
Forschungsgebiete:
α-Synuclein-IN-21 is an α-synuclein (α-Syn) aggregation inhibitor with an IC50 of 1.6 μM. α-Synuclein-IN-21 stabilizes the secondary conformation of α-synuclein monomers, inhibits β-sheet formation, reduces oligonucleation during the aggregation lag phase, dissociates preformed aggregates, and blocks re-aggregation. α-Synuclein-IN-21 reduces α-synuclein inclusions in neuronal cells and scavenges ROS. α-Synuclein-IN-21 can be used for the research of Parkinson's disease .
Art. -Nr.: HY-184819
CAS. Nr.: 2883627-56-1
Forschungsgebiete:
α-Synuclein-IN-24 is an α-synuclein (α-Syn) aggregation inhibitor with an IC50 of 4.0 μM. α-Synuclein-IN-24 stabilizes the secondary conformation of α-synuclein monomers, inhibits β-sheet formation, reduces oligonucleation during the aggregation lag phase, dissociates preformed aggregates, and blocks reaggregation. α-Synuclein-IN-24 reduces α-synuclein inclusions in neuronal cells and scavenges ROS. α-Synuclein-IN-24 can be used for the research of Parkinson's disease .
Art. -Nr.: HY-184847
CAS. Nr.: 2883627-66-3
Target:
Forschungsgebiete:
α-Synuclein-IN-25 is a quinone-acid hybrid and also an α-synuclein aggregation inhibitor with an IC50 of 3.0 μM. α-Synuclein-IN-25 dissociates preformed α-Syn aggregates, inhibits their re-aggregation, scavenges reactive oxygen species, and reduces the formation of α-Syn inclusions in neuronal cells. α-Synuclein-IN-25 can be used in the research of Parkinson's disease .
Art. -Nr.: HY-184817
CAS. Nr.: 2883627-63-0
Forschungsgebiete:
α-Synuclein-IN-22 is an α-Synuclein inhibitor with an IC50 of 2.7 μM against human α-Syn. α-Synuclein-IN-22 exerts anti-aggregation effects by stabilizing the native conformation of α-Syn, inhibiting the formation of β-sheet aggregates and inclusion bodies, and dissociating mature fibrils into functional monomers. α-Synuclein-IN-22 scavenges ROS and shows low cytotoxicity. α-Synuclein-IN-22 can be used in research related to Parkinson's disease .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
